Abstract:Protein aggregation is common to dozens of diseases including prionoses, diabetes, Parkinson’s and Alzheimer’s. Over the past 15 years, there has been a paradigm shift in understanding the structural basis for these proteinopathies. Precedent for this shift has come from investigation of soluble Aβ oligomers (AβOs), toxins now widely regarded as instigating neuron damage leading to Alzheimer’s dementia. Toxic AβOs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. The AD-like cellular pathologies induced by AβOs suggest their impact provides a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Alternative ideas for triggering mechanisms are being actively investigated. Some research favors insertion of AβOs into membrane, while other evidence supports ligand-like accumulation at particular synapses. Over a dozen candidate toxin receptors have been proposed. AβO binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca2+ overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of AβOs have been identified, a remaining question is which oligomer is the major pathogenic culprit. The possibility has been raised that more than one species plays a role. Despite some key unknowns, the clinical relevance of AβOs has been established, and new studies are beginning to point to co-morbidities such as diabetes and hypercholesterolemia as etiological factors. Because pathogenic AβOs appear early in the disease, they offer appealing targets for therapeutics and diagnostics. Promising therapeutic strategies include use of CNS insulin signaling enhancers to protect against the presence of toxins and elimination of the toxins through use of highly specific AβO antibodies. An AD-dependent accumulation of AβOs in CSF suggests their potential use as biomarkers and new AβO probes are opening the door to brain imaging. Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer’s disease.

Bacterial Extracellular DNA Promotes β-Amyloid Aggregation

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Gut-derived Β-Amyloid: Likely a Centerpiece of the Gut–brain Axis Contributing to Alzheimer’s Pathogenesis

Mechanistic insights into the role of amyloid-β in innate immunity

Gram-Negative Bacterial Molecules Associate with Alzheimer Disease Pathology

Effect of Bacterial Amyloid Protein Phenol-Soluble Modulin Alpha 3 on the Aggregation of Amyloid Beta Protein Associated with Alzheimer's Disease.

The role of the biofilm of Porphyromonas gingivalis in driving amyloid beta secretion and aggregation

LIPOPOLYSACCHARIDE AND E. COLI PROTEINS AND DNA IN ALZHEIMER’S DISEASE BRAINS COMPARED TO CONTROLS

Alzheimer's Progenitor Amyloid‐β Targets and Dissolves Microbial Amyloids and Impairs Biofilm Function

The Early Events That Initiate Β-Amyloid Aggregation in Alzheimer’s Disease

Lipopolysaccharide Associates with Amyloid Plaques, Neurons and Oligodendrocytes in Alzheimer’s Disease Brain: A Review

The menace within: bacterial amyloids as a trigger for autoimmune and neurodegenerative diseases

Evidence supportive of a bacterial component in the etiology for Alzheimer's disease and for a temporal-spatial development of a pathogenic microbiome in the brain

Time-Dependent DNA Condensation Induced by Amyloid β-Peptide

Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans

Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid

Extracellular Vesicle-Associated Aβ Mediates Trans-Neuronal Bioenergetic and Ca2+-Handling Deficits in Alzheimer's Disease Models

Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease

Why does the Aβ peptide of Alzheimer share structural similarity with antimicrobial peptides?

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Aβ1-16 Can Aggregate and Induce the Production of Reactive Oxygen Species, Nitric Oxide, and Inflammatory Cytokines.